Union Home Secretary Ajay Bhalla mentioned there shall be interim allocation and provide of the life-saving injection to the states and UTs from 21 to 30 April
New Delhi: The manufacturing of life-saving Remdesivir injection used for the remedy of COVID-19 sufferers and is at present in shortage within the nation, shall be augmented to 74 lakh items by subsequent month from 38.80 lakh items now, the Union residence ministry mentioned.
The ministry additionally requested the states and Union territories (UTs) to make sure seamless provide and transport of Remdesivir.
Union Home Secretary Ajay Bhalla, in a letter to chief secretaries of all states and Union territories (UTs) on Thursday, additionally conveyed that there shall be interim allocation and provide of the life-saving injection to the states/UTs from 21 to 30 April.
Bhalla mentioned a monitoring mechanism has been arrange underneath the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers by means of the National Pharmaceuticals Pricing Authority (NPPA) and the Drugs Controller General of India for monitoring and coordinating the availability of COVID-19 medication each day, with pharmaceutical associations, manufacturing corporations and state governments.
“The supply of Remdesivir injection and imported drug Toclizumab is under severe constraint due to sharp increase in demand. Several steps have been taken to augment the production capacity of the seven licensed manufacturers of Remdesivir injection in the country from 38.80 lakh units per month to 74 lakh units per month by early May 2021,” the letter mentioned.
The residence secretary additionally mentioned the Ministry of Health and Family Welfare (MoHFW) and the Department of Pharmaceutical (DoP) have communicated to the states/UTs about an interim allocation, from 21 to 30 April, for provide of Remdesivir by all of the licensed home producers.
“In view of the above, I would urge you to issue necessary instructions to all the authorities concerned to take all measures for compliance with the above allocation and subsequent allocations to be made by MoHFW and DOP in a smooth and timely manner to ensure seamless supply and transport of Remdesivir to States/UTs concerned,” he mentioned.
Bhalla mentioned any disruption or hindrance to the motion of this drug, might have unintended antagonistic impact to the nation’s battle towards COVID-19 .
“I would also request you to personally monitor the supply of essential medicines required under COVID Treatment Protocol in your UT and appoint Nodal Officers who will be responsible for un-restricted and timely movement of Remdesivir within their UT as per allocation made by MoHFW,” he added.